Argenx Se (ARGX) Income towards Parent Company (2016 - 2026)
Argenx Se's (ARGX) quarterly Income towards Parent Company came in at $472.0 million in Q2 2026, up 92.37% on a YoY basis from $245.4 million in Q2 2025, and up 28.96% quarter-over-quarter from $366.0 million in Q1 2026.
Analysis
Argenx Se (ARGX) Income towards Parent Company (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Income towards Parent Company for 11 consecutive years, with $472.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income towards Parent Company rose 92.37% year-over-year to $472.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 34.01% YoY), and the FY2025 full-year result was $1.3 billion, up 55.1% from the prior year.
- Income towards Parent Company rose to $472.0 million in Q2 2026 per ARGX's latest filing, from $366.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $774.2 million in Q4 2024 and bottomed at -$235.0 million in Q3 2022.
- Historically, Income towards Parent Company has averaged $108.8 million across 5 years, with a median of $97500.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 1157.6% in 2022, then jumped 880.62% in 2024.
- Over 5 years, Income towards Parent Company stood at -$38.6 million in 2022, then slumped by 156.84% to -$99.2 million in 2023, then surged by 880.62% to $774.2 million in 2024, then tumbled by 31.16% to $532.9 million in 2025, then fell by 11.44% to $472.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $472.0 million, $366.0 million, and $532.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 472.00 Mn |
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 532.95 Mn |
| Sep 30, 2025 | 344.26 Mn |
| Jun 30, 2025 | 245.36 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | 774.16 Mn |
| Sep 30, 2024 | 91.41 Mn |
| Jun 30, 2024 | 29.07 Mn |
| Mar 31, 2024 | -61.60 Mn |
| Dec 31, 2023 | -99.17 Mn |
| Sep 30, 2023 | -72.64 Mn |
| Jun 30, 2023 | -94.37 Mn |
| Mar 31, 2023 | -28.87 Mn |
| Dec 31, 2022 | -38.61 Mn |
| Sep 30, 2022 | -235.04 Mn |
| Jun 30, 2022 | -208.75 Mn |
| Mar 31, 2022 | -227.19 Mn |
| Dec 31, 2021 | -237.82 Mn |
| Sep 30, 2021 | -233.61 Mn |